Shameemah Abrahams

Shameemah Abrahams

Auto-generated profile, based on publicly available information

Shameemah Abrahams

Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Neuroscience
Verified
Journal Article
Closed access
SAShameemah Abrahams
Shameemah Abrahams
WHWilliam L. Haylett
William L. Haylett
GJGlynis Johnson
Glynis Johnson
JCJonathan A. Carr
Jonathan A. Carr
SBSoraya Bardien
Soraya Bardien

19 September 2013 in British Journal of Sports Medicine
Verified
Journal Article
Closed access
SAShameemah Abrahams
Shameemah Abrahams
SFSarah Mc Fie
Sarah Mc Fie
JPJon Patricios
Jon Patricios
MPMichael Posthumus
Michael Posthumus
ASAlison V September
Alison V September
Concussion is a common sports injury with approximately 1.6–3.8 million sport-related concussions reported in the USA annually. Identifying risk factors may help in preventing these injuries. This systematic review aims to identify such risk factors. Three electronic databases; ScienceDirect, PubMed and SpringerLink, were searched using the keywords ‘RISK FACTORS’ or ‘PREDISPOSITION’ in conjunction with ‘SPORT’ and ‘CONCUSSION’. Based on the inclusion and exclusion criteria, 13 628 identified titles were independently analysed by two of the authors to a final list of 86 articles. Only articles with a level of evidence of I, II and III were included according to robust study design and data analysis. The level of certainty for each risk factor was determined. A high level of certainty for increased risk of a subsequent concussion in athletes sustaining more than one previous concussion was reported in 10 of 13 studies. Further, a high level of certainty was assigned to match play with all 29 studies reporting an increased concussion risk during matches. All other risk factors were evaluated as having a low level of certainty. Although several risk factors were identified from the appraised studies, prospective cohort studies, larger sample sizes, consistent and robust measures of risk should be employed in future research.


30 June 2017 in Journal of Sports Sciences
Verified
Journal Article
Closed access
SFSarah Mc Fie
Sarah Mc Fie
SAShameemah Abrahams
Shameemah Abrahams
JPJon Patricios
Jon Patricios
JSJason Suter
Jason Suter
MPMichael Posthumus
Michael Posthumus
ASAlison Victoria September
Alison Victoria September
The objective was to investigate the relationship between Catechol-O-methyltransferase (COMT) rs4680 and serotonin-transporter-linked polymorphic region (5-HTTLPR) genotypes with concussion history and personality traits. Rugby players (“all levels”: n = 303), from high schools (“junior”, n = 137), senior amateur, and professional teams (“senior”, n = 166), completed a self-reported concussion history questionnaire, Cloninger’s Tridimensional Personality Questionnaire, and donated a DNA sample. Participants were allocated into control (non-concussed, n = 140), case (all) (previous suspected or diagnosed concussions, n = 163), or case (diagnosed only) (previous diagnosed concussion, n = 140) groups. COMT rs4680 Val/Val genotypes were over-represented in controls in all levels (P = 0.013, OR:2.00, 95% CI:1.15–3.57) and in juniors (P = 0.003, OR:3.57, 95% CI:1.45–9.09). Junior Val/Val participants displayed increased “anticipatory worry” (P = 0.023). The 5-HTTLPR low expressing group was under-represented in controls when all levels were considered (P = 0.032; OR:2.02, 95% CI:1.05–3.90) and in juniors (P = 0.021; OR:3.36, 95% CI:1.16–9.72). Junior 5-HTTLPR low and intermediate expressing groups displayed decreased “harm avoidance” (P = 0.009), “anticipatory worry” (P = 0.041), and “fear of uncertainty” (P < 0.001). This study provides preliminary indications that personality associated genetic variants can influence concussion in rugby.

27 May 2021 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
DCDevina Chetty
Devina Chetty
SAShameemah Abrahams
Shameemah Abrahams
RCRiaan van Coller
Riaan van Coller
JCJonathan Carr
Jonathan Carr
CKColin Kenyon
Colin Kenyon
SBSORAYA BARDIEN
SORAYA BARDIEN

1 September 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
SAShameemah Abrahams
Shameemah Abrahams
HMHayley C. Miller
Hayley C. Miller
CLCarl Lombard
Carl Lombard
FWFrancois H. van der Westhuizen
Francois H. van der Westhuizen
SBSORAYA BARDIEN
SORAYA BARDIEN
Mitochondrial dysfunction has been proposed as one of the pathobiological underpinnings in Parkinson's disease. Environmental stressors, such as paraquat, induce mitochondrial dysfunction and promote reactive oxygen species production. Targeting oxidative stress pathways could prevent mitochondrial dysfunction and thereby halt the neurodegeneration in Parkinson's disease. Since curcumin is touted as an antioxidant and neuroprotective agent, the aim of this study was to investigate if curcumin is a suitable therapy to target mitochondrial dysfunction in Parkinson's disease using a paraquat-toxicity induced model in fibroblasts from LRRK2-mutation positive Parkinson's disease individuals and healthy controls. The fibroblasts were exposed to five treatment groups, (i) untreated, (ii) curcumin only, (iii) paraquat only, (iv) pre-curcumin group: with curcumin for 2hr followed by paraquat for 24hr and (v) post-curcumin group: with paraquat for 24hr followed by curcumin for 2hr. Mitochondrial function was determined by measuring three parameters of mitochondrial respiration (maximal respiration, ATP-associated respiration, and spare respiratory capacity) using the Seahorse XFe96 Extracellular Flux Analyzer. As expected, paraquat effectively disrupted mitochondrial function for all parameters. Pre-curcumin treatment improved maximal and ATP-associated respiration whereas, post-curcumin treatment had no effect. These findings indicate that curcumin may be most beneficial as a pre-treatment before toxin exposure, which has implications for its therapeutic use. These promising findings warrant future studies testing different curcumin dosages, exposure times and curcumin formulations in larger sample sizes of Parkinson's disease and control participants.